Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 4/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.53 |
| ▸ | CLK3 | P49761 | 2/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.53 |
| ▸ | CLK2 | P49760 | 2/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.48 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148685 | 1.00 | CLK1 (0.53) | CLK1DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL2993704 | 1.00 | CLK1 (0.53) | CLK1DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL3393661 | 0.99 | CLK1 (0.52) | CLK1DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL3393655 | 0.99 | CLK1 (0.52) | CLK1DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL3393650 | 0.99 | CLK1 (0.52) | CLK1DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL4641944 | 0.91 | CLK1 (0.48) | CLK1DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL45468 | 0.91 | CLK1 (0.48) | CLK1DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL45467 | 0.91 | CLK1 (0.48) | CLK1DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL4955057 | 0.90 | CLK1 (0.47) | CLK1DYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL4641199 | 0.90 | CLK1 (0.47) | CLK1DYRK1ADYRK2DYRK1BDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION | 2010-11-11 | — | — | US | claimed |
| US-20100184774-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION | 2010-07-22 | — | — | US | claimed |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | GLAXOSMITHKLINE LLC | 2007-08-02 | — | — | US | claimed |
| US-20240352418-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | MEGAKARYON CORPORATION (JP) | 2024-10-24 | — | — | US | disclosed |
| EP-4342982-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | Megakaryon Corporation (JP) | 2024-03-27 | — | — | EP | disclosed |
| WO-2022265117-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | 株式会社メガカリオン | 2022-12-22 | — | — | WO | disclosed |
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION | 2010-11-11 | — | — | US | disclosed |
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION | 2010-11-11 | — | — | US | disclosed |
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION | 2010-11-11 | — | — | US | disclosed |
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION | 2010-11-11 | — | — | US | disclosed |
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION | 2010-11-11 | — | — | US | disclosed |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | GLAXOSMITHKLINE LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | GLAXOSMITHKLINE LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | GLAXOSMITHKLINE LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | GLAXOSMITHKLINE LLC | 2007-08-02 | — | — | US | disclosed |
| WO-2006135712-A3 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORP (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006135712-A3 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORP (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006135712-A2 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135712-A2 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135712-A2 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | HYPK, HIPK3, HIPK1 | CLK1 175/4885DYRK1A 111/4885DYRK2 140/4885 |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | HCLS1, HIPK3, HYPK | CLK1 523/4885DYRK1A 638/4885DYRK2 850/4885 |
| US-20100184774-A1 | METHODS OF TREATMENT | OPRL1, BRCA1, PKD1 | CLK1 4211/4885DYRK1A 2870/4885DYRK2 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.